Skip to main content
SpringerLink
Log in

The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The goal of this study was to assess the efficacy of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant chemotherapy (NACT) in locoregionally advanced nasopharyngeal carcinoma (NPC). A total of 120 patients with stage III-IVB NPC treated with NACT followed by IMRT alone (39 patients, arm 1) or CCRT (81 patients, arm 2) between May 2009 and June 2012 were eligible for study inclusion. NACT consisted of docetaxe (DOC, 60 mg/m2, day 1) and cisplatin (DDP, 100 mg/m2, days 1–5, every 3 weeks). Concurrent chemotherapy was nedaplatin (NDP, 25 mg/m2, days 1–3, every 3 weeks). The median follow-up period was 41 (range 5–52) months, and the 3-year overall survival, distant metastases-free survival, locoregional relapse-free survival, and progression-free survival rates of arm 1 and arm 2 were 83.3 and 87.4 % (P = 0.516), 81.7 and 79.6 % (P = 0.596), 86 and 92.3 % (P = 0.920), 76.4 and 76.4 % (P = 0.709), respectively. During radiotherapy, the most commonly recorded grade 3/4 adverse events were anemia (7.7 vs. 4.9 %), leucopenia (10.2 vs. 3.7 %), thrombocytopenia (12.8 vs. 3.7 %), neutropenia (15.4 vs. 6.2 %), nausea/vomiting (7.7 vs. 12.3 %), stomatitis/mucositis (38.5 vs. 46.9 %), xerostomia (35.9 vs. 30.8 %), dermatitis (7.7 vs. 7.4 %), and fatigue(15.4 vs. 17.2 %) for arm 1 and arm 2. The results of this study indicated that added concurrent chemotherapy to IMRT after neoadjuvant DOC and DDP treatment for locoregionally advanced NPC was probably not be necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Lyon: IARC Scientific Publications; 2007.

    Google Scholar 

  2. Chua Daniel TT, Ma Jun, Sham Jonathan ST, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J clin oncol. 2005;12:081.

    Google Scholar 

  3. Hepeng J. A controversial bid to thwart the ‘Cantonese cancer’. Science. 2008;321(5893):1154–5.

    Article  CAS  PubMed  Google Scholar 

  4. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65:161–8.

    Article  PubMed  Google Scholar 

  5. He XY, Liu TF, He SQ, et al. Late course accelerated hyper-fractionated radiotherapy of nasopharyngeal carcinoma (LCAF). Radiother Oncol. 2007; 8529–3.

  6. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038–44.

    Article  CAS  PubMed  Google Scholar 

  7. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–7.

    Article  PubMed  Google Scholar 

  8. OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013;24:2136–46.

    Article  CAS  PubMed  Google Scholar 

  9. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. MAC-NPC collaborative group: chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56.

    Article  CAS  PubMed  Google Scholar 

  10. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60:1440–50.

    Article  PubMed  Google Scholar 

  11. Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. Int J Radiat Oncol Biol Phys. 2009;75:1481–6.

    Article  PubMed  Google Scholar 

  12. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatinradiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242–9.

    Article  CAS  PubMed  Google Scholar 

  13. Ji X, Xie C, Hu D, Fan X, Zhou Y, Zheng Y. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. PLoS One. 2013;8:e56208.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Jianhua Xu, Xia He, Kong Cheng, et al: Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity. Head&Neck. 10.1002, 2014.

  15. Chitapanarux Imjai, Lorvidhaya Vicharn, Tharavichitkul Ekasit, et al. A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer. Auris Nasus Larynx. 2011;38:108–12.

    Article  PubMed  Google Scholar 

  16. Marshall R, Diane M, Cesar R, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:17.

    Article  Google Scholar 

  17. Fen X, Qin W, Bao W, et al. Arterial interventional chemotherapy and IMRT with concurrent chemotherapy for nasopharyngeal carcinoma with intracranial involvement. Oncol Lett. 2013;6:427–31.

    PubMed Central  PubMed  Google Scholar 

  18. Airoldi M, Gabriele AM, Gazaro M, et al. Induction chemo-Therapy with cispltin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol. 2009;92:105–10.

    Article  CAS  PubMed  Google Scholar 

  19. Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110:398–403.

    Article  PubMed  Google Scholar 

  20. Huang Peiyu, Cao Kajia, Guo Xiang, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48:1038–44.

    Article  CAS  PubMed  Google Scholar 

  21. Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23:427–35.

    Article  CAS  PubMed  Google Scholar 

  22. Ekenel M, Keskin S, Basaran M, Ozdemir C, Meral R, Altun M, et al. Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2011;47:660–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. School of Nuclear Science and Technology, University of South China, 28 Changsheng West Road, Hengyang, 421001, Hunan, People’s Republic of China

    Lei Zhang & Ping-jing Cheng

  2. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, People’s Republic of China

    Guo-ping Shan & Pu Li

Authors
  1. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guo-ping Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ping-jing Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping-jing Cheng.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Shan, Gp., Li, P. et al. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Med Oncol 32, 41 (2015). https://doi.org/10.1007/s12032-015-0505-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0505-2

Keywords

Search

Navigation